The European Medicines Agency recommended using Novavax's COVID-19 vaccine Nuvaxovid as a booster dose in the adult population, as the bloc continued preparations for a possible resurgence of the coronavirus during winter. The Novaxovid jab can be administered as a booster dose both to people initially vaccinated by the same vaccine or any other approved COVID-19 shot, the EMA said.
The agency's decision comes as health authorities hope undecided people who objected to receiving the so-called mRNA vaccines, such as those developed by Moderna and Pfizer, will turn to the decades-old vaccine technology. However, hopes weren't fulfilled so far, forcing Novavax to significantly reduce its annual revenue outlook last month due to limited vaccine demand.
